Nussbaum Ran
- SEC CIK
- 0001609805
In the past year, 1 open-market sale filing worth $85.0M and no purchases.
Current role at each company
- LBRX LB Pharmaceuticals IncDirectoras of Jun 5, 2026
- KROS Keros Therapeutics, Inc.Director, 10% Owneras of Oct 17, 2025
- URGN UroGen Pharma Ltd.Directoras of Feb 28, 2023
- ELOX Eloxx Pharmaceuticals, Inc.Directoras of Jun 17, 2022
Open-market trades in the past year
Open-market purchases (P) and sales (S) filed in the last 365 days, not counting derivative securities or duplicate filings. Values leave out price outliers.
- Bought
- –
- 0 filings
- Sold
- $85.0M
- 1 filing
- Net
- −$85.0M
- Bought minus sold
- Companies
- 1
- With open-market trades
Trades
Every Form 4 that lists Nussbaum Ran as a reporting owner, including filings made jointly with others, grouped by company. Each row adds up one type of transaction in one filing. Only open-market purchases (P) and sales (S) are shown by default.
KROS Keros Therapeutics, Inc.
Director, 10% Owner1 trade
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Oct 17, 2025 (view filing)5:53 PM ET | Oct 15 | 2 days | Kariv Tomer and 7 othersDirector, 10% Owner | SSaleCommon Stock, $0.0001 par value per share | −4.79M | $17.75 | −$85.0M | −100.0%0 after | 4 lots |
LBRX LB Pharmaceuticals Inc
Director1 trade
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Sep 16, 2025 (view filing) | Sep 12 | 4 days | Nussbaum RanDirector | PPurchase | +1.00M | $15.00 | +$15.0M | +242.9%1.41M after |